Seminars in Oncology
Volume 31, Issue 1 , Pages 33-36, February 2004

Nonmyeloablative reduced-intensity transplantation in multiple myeloma

  • Athanasios Anagnastopoulos

      Affiliations

    • Department of Blood and Marrow Transplantation, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
  • ,
  • Ana Aleman

      Affiliations

    • Department of Blood and Marrow Transplantation, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
  • ,
  • Sergio Giralt

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Sergio Giralt, MD, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    • Department of Blood and Marrow Transplantation, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA

Abstract 

Reduced-intensity conditioning (RIC) allogeneic transplants are being performed more frequently in a variety of hematologic malignancies. The aim is to exploit the graft-versus-tumor (GVT) effect seen after allografting without the toxicities of myeloablative conditioning. RIC regimens are being extensively explored for salvage therapy of myeloma. Although nonrelapse mortality rates are acceptable, relapse remains the most common cause of treatment failure. New combinations and novel therapies need to be explored to improve outcomes. This strategy should also be employed earlier in the course of the disease.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0093-7754(03)00562-1

doi:10.1053/j.seminoncol.2003.10.019

Seminars in Oncology
Volume 31, Issue 1 , Pages 33-36, February 2004